Eli Lilly and Company

Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges, focused on the discovery and development of a novel class of “protein-like polymers” to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Ampersand Biomedicines is a biotechnology company that focuses on developing innovative therapeutic solutions aimed at treating diseases directly at the site of action. Utilizing its proprietary Address, Navigate, Design (AND)™ Platform, the company integrates a localizing element for precision targeting with an actuator tailored for specific disease modification. This approach allows for the exploration and treatment of a wide array of diseases across various areas of the body, enhancing the potential for effective medical interventions.

ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. The company is advancing several product candidates, including sepofarsen, which is in phase II/III clinical trials for Leber's congenital amaurosis 10, and QR-421a, currently in phase 1/2 trials for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in phase 1/2 trials for autosomal dominant retinitis pigmentosa, while QR-504a has commenced its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR has established collaborations with leading medical and research institutions, including General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is dedicated to developing innovative treatments for patients with severe genetic rare diseases.

NanoSyrinx is a biotechnology company focused on developing an innovative system for the targeted delivery of therapeutic proteins and peptides directly into the cytosol of cells. By employing synthetic biology techniques, the company aims to create a groundbreaking method for drug delivery that enhances the efficacy, safety, and cost-effectiveness of treatments in the biopharmaceutical sector. This novel approach allows for precise delivery of therapeutic agents, potentially improving treatment outcomes for patients by ensuring that the drugs reach their intended cellular targets.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics.

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Prism BioLab is focused on drug discovery and development, utilizing its proprietary PepMetics Technology to create therapeutic agents. The company specializes in treatments for non-oncology indications, particularly targeting conditions such as pulmonary fibrosis and other incurable diseases. By leveraging its innovative platform, Prism BioLab aims to provide effective solutions for these challenging health issues.

POINT Biopharma Global Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of radioligand therapies for cancer treatment. The company is focused on creating a robust platform for the clinical development of radiopharmaceuticals, utilizing advanced radioisotopes such as Actinium-225 and Lutetium-177. POINT Biopharma's product pipeline includes several candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, among others. By leveraging a combination of innovative manufacturing technology and direct-to-patient targeting, POINT Biopharma aims to transform theragnostic drug development and enhance the commercialization of radioligands in the fight against cancer.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders, including obesity and related conditions such as type 2 diabetes and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways that maintain energy balance, thereby addressing the underlying causes of these disorders. OrsoBio's commitment to innovation seeks to revolutionize treatment options for individuals suffering from metabolic dysfunctions, including lipodystrophies and other obesity-associated complications. Through its research and development efforts, OrsoBio strives to enhance patients' energy metabolism and improve their overall health outcomes.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. The company is advancing several product candidates, including sepofarsen, which is in phase II/III clinical trials for Leber's congenital amaurosis 10, and QR-421a, currently in phase 1/2 trials for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in phase 1/2 trials for autosomal dominant retinitis pigmentosa, while QR-504a has commenced its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR has established collaborations with leading medical and research institutions, including General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is dedicated to developing innovative treatments for patients with severe genetic rare diseases.

Rezo Therapeutics is a biotechnology company that focuses on developing precision therapeutics by mapping disease networks. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo integrates various technologies, including proteomics, genetics, structural biology, chemistry, and bioinformatics, to create comprehensive molecular maps of diseases. This innovative approach enhances the identification of novel targets and therapies, particularly in oncology, where Rezo initially concentrates its efforts. The company aims to expand its therapeutic focus through collaborations and partnerships, positioning itself at the forefront of advancing treatment options across multiple disease areas.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.

Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

MiNA Therapeutics is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing small activating RNA medicines aimed at restoring normal cell function in patients. Established in 2008, the company is advancing its pipeline with products such as MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA in conjunction with Pembrolizumab for advanced solid tumors. MiNA's innovative approach leverages gene activation mechanisms to transform the treatment landscape for cancer and other serious diseases, enabling healthcare professionals to better address these conditions.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

Disarm Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients suffering from neurological diseases. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company aims to create disease-modifying drugs that prevent axonal degeneration, which is a key factor in various neurological disorders. Disarm's portfolio addresses conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, providing potential treatments for acute diseases affecting the central, ocular, and peripheral nervous systems. As of late 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.

Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.

AbCellera is an antibody discovery and development company focused on overcoming the limitations of traditional discovery methods. By utilizing its integrated platform, AbCellera's experts rapidly search a diverse array of antibodies to identify the most effective candidates for clinical development. This streamlined approach allows for faster movement to clinical trials, ultimately benefiting patients sooner. The company has a strong track record of collaborating with both emerging biotechnology firms and established pharmaceutical companies, providing optimized solutions tailored to their needs. AbCellera employs proprietary technology and advanced data science to enhance its antibody discovery process, positioning itself as a strategic partner in the biopharmaceutical industry.

Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

Loxo Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for patients with genetically defined cancers in the United States. Founded in 2013 and headquartered in Stamford, Connecticut, the company is dedicated to rapidly advancing cancer treatments that demonstrate significant clinical potential. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) currently undergoing various clinical trials for multiple tumor types, including lung, head and neck, melanoma, colorectal, sarcoma, and breast cancers. In addition to larotrectinib, Loxo Oncology is advancing preclinical programs, including LOXO-195, a candidate addressing resistance mechanisms, as well as inhibitors targeting RET fusion proteins and FGFR isoforms. The company collaborates with several partners, including Array BioPharma and Illumina, to enhance its drug discovery and development processes. Loxo Oncology aims to leverage insights from diagnostic advancements to identify actionable targets and develop innovative treatments tailored to patients with specific genetic vulnerabilities.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

AurKa Pharma is a biopharmaceutical company focused on developing a single compound aimed at treating solid tumors. The company has completed GLP toxicology studies and plans to initiate clinical development, pending regulatory approval. The primary objective is to demonstrate clinical proof-of-concept of efficacy in solid tumors, with the potential to explore additional cancer indications in the future. Through this targeted approach, AurKa Pharma aims to enhance treatment options for patients suffering from cancer.

Entrega Bio offers a proprietary technology that makes injectable substances available orally. Its technology has the potential to deliver a wide variety of biological molecules, drug substances, and nanoparticles. Entrega Bio collaborates with pharma and non-pharma industry partners to develop the platform for innovative therapeutic and diagnostic modalities. This platform enables novel applications in a variety of fields such as disease management and tracking in the burgeoning mobile health arena. Entrega Bio is based in Boston, Massachusetts, United States.

Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.

CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics primarily for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various cancers such as biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials targeting advanced or metastatic HER2-expressing cancers. Zymeworks utilizes a combination of proprietary molecular modeling, simulation software, and high-performance computing to optimize therapeutic antibodies and other protein-based treatments. The company has established strategic partnerships with several leading pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Additionally, Zymeworks is advancing a preclinical pipeline that includes candidates for oncology and other therapeutic areas, reflecting its commitment to addressing unmet medical needs.

Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York that focuses on discovering and developing therapies targeting phosphoinositide (PI) signaling pathways. Established in 2015, the company aims to create novel small molecules that address serious medical conditions, particularly cancer and metabolic diseases. By honing in on unique enzyme targets involved in critical cellular processes such as cell division, growth, trafficking, and signaling, Petra Pharma seeks to develop innovative treatments that can enhance human health and provide new options for healthcare providers.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing the evolving needs of patients worldwide through the development and manufacturing of innovative pharmaceuticals. The company focuses on a wide range of therapeutic areas, including oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic conditions. Novartis is also active in medical nutrition, providing specialized nutritional solutions for individuals with specific dietary needs. Additionally, its animal health division develops advanced medicines aimed at improving the health and welfare of pets, farm animals, and farmed fish. The Genomics Institute of the Novartis Research Foundation plays a crucial role in bridging basic science and preclinical drug discovery, employing nearly 600 scientists to enhance drug development processes. Through its diverse portfolio and commitment to research, Novartis aims to transform patient care and improve health outcomes globally.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics primarily for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various cancers such as biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials targeting advanced or metastatic HER2-expressing cancers. Zymeworks utilizes a combination of proprietary molecular modeling, simulation software, and high-performance computing to optimize therapeutic antibodies and other protein-based treatments. The company has established strategic partnerships with several leading pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Additionally, Zymeworks is advancing a preclinical pipeline that includes candidates for oncology and other therapeutic areas, reflecting its commitment to addressing unmet medical needs.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

Alnara Pharmaceuticals, Inc. specializes in the development of novel protein therapeutics aimed at treating metabolic diseases. The company employs an innovative strategy that emphasizes the creation of effective protein therapies designed for oral delivery directly to the gastrointestinal tract, ensuring that these treatments are not absorbed into the bloodstream. This unique approach positions Alnara Pharmaceuticals to address specific metabolic conditions with targeted therapeutic solutions.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.

ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.

GlycoFi is a biotech firm based in Lebanon, New Hampshire, focused on developing biotherapeutics through its innovative glycan optimization technology. The company has engineered a library of yeast strains that enable precise human glycosylation, resulting in therapeutic proteins suitable for drug development. GlycoFi aims to establish its own pipeline of therapeutic products while also collaborating with other pharmaceutical companies to enhance their drug offerings. Founded in 2000, GlycoFi operates as a subsidiary of Merck & Co., Inc., further expanding its capabilities in the biotherapeutics landscape.

Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.

Applied Molecular Evolution, Inc. discovers, optimizes, and develops human bio-therapeutics. Applied Molecular Evolution offers AMEsystem technology platform for the development of human biotherapeutic candidates.

Pharmaserve-Lilly S.A.C.I provides researches, distributes, and commercializes pharmaceutical products in Greece.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.